Unconfigured Ad
Collapse
X
-
I heard a rumor that 454 is seriously decreasing its price level in the US. Can anybody confirm this? It is about time too, with the HiSeq making sequencing incredibly cheap...
-
-
My understanding is that 454 long reads are for whole-genome shotgun only, not amplicon protocol. At least this is the case for the initial release. Which means they won't be useful for 16S diversity studies which is a shame as that would be the biggest win for us (for accurate species level determination).
Also, as GW_OK pointed out, 454 long reads were announced several years ago and we still don't have a firm shipping date (I heard Q2/Q3 was the latest estimate). Plus you need an instrument upgrade, plus they are not available for 454 Jr (which will annoy a bunch of people). Also it's more like 700bp median than 1kb and the quality drop-off is quite severe towards the read tail.
454 long reads (i.e. 700 vs 500) may be useful for a limited number of de novo assembly projects but I don't think they are critical, and it is certainly true that the cost is prohibitive for many users.Last edited by nickloman; 04-30-2011, 04:34 AM.
Leave a comment:
-
-
Guest replied5kb reads trimmed to 500 usable with QV's in the single digits. There are not entering any real application space for a long time.Originally posted by krobison View PostThe other player in this space will be PacBio; their reads are apparently pushing 5Kb. If you are primarily using long reads to scaffold short ones, then the ~80% single pass accuracy may not be an issue.
Of course, getting an instrument will set you back a lot more than any of these others . But, there seem to be enough in the field that it is likely one could get access for a project without buying one.
Roche will hold its niche until someone has high quality long reads. It's still a year out or more on the PGM. They need to to something about the cost per base though. Even 454 Jr runs are ridiculous.
Leave a comment:
-
-
Longer reads are definitely worth more. The question is how much more. Currently you are looking at 50-100x more per base for 454 reads than for Illumina or SOLiD reads.
On the other hand, people are still doing Sanger sequencing -- that is 50-100X more expensive per base than 454 reads. So it goes back to the fact that there are lots of assays that do not benefit much from vastly more sequence.
--
Phillip
Leave a comment:
-
-
surely the inverse of this statement is also true. What applications do you need tiled short reads for that cannot be addressed with long reads (of sufficient qual).
What applications do you need 1000bp or more for that can't be broken down into short uniquely barcoded amplicons tiled across regions?
That's what makes our jobs so much fun!
Leave a comment:
-
-
Then I'd be dreaming
In this scenario would I also be cruising down the Pacific Coast Highway in a Ferrari with Elle McPherson in the passenger seat?Originally posted by clivey View PostWhat if
Your reads were over 100kb, very accurate and you had a mountain of them ?
Leave a comment:
-
-
What if
Your reads were over 100kb, very accurate and you had a mountain of them ?
Leave a comment:
-
-
I absolutely agree. I remember them first talking about 1k reads way back in 2007-8 or whenever Titanium was first coming out. It was always going to drop in the next 6 months and was then always pushed back.Originally posted by RCJK View PostIt's taken Roche way to long to launch this and they are too quiet regarding any other plans they may have. I believe they have licensed the same semiconductor tech as Ion Torrent so I'm waiting for an announcement one day of a similar platform....
And we were always, always asking about when they were going to automate emPCR. I wonder if they can license the OneTouch from iotorrent, lol.
The 454 is quickly becoming the has-been of the field.
Leave a comment:
-
-
The other player in this space will be PacBio; their reads are apparently pushing 5Kb. If you are primarily using long reads to scaffold short ones, then the ~80% single pass accuracy may not be an issue.
Of course, getting an instrument will set you back a lot more than any of these others . But, there seem to be enough in the field that it is likely one could get access for a project without buying one.
Leave a comment:
-
-
it would also be useful if roche automated their emulsion pcr-breaking and enrichment steps. SOLiD have the ez system, ion torrent will have the one touch. Doing any of these processes manually is a right pain. I'm suprised roche haven't done something about this.
Leave a comment:
-
-
How about PacBio machine that claimed a maximun read length of 3kb with an average of 1kb? The only problem is they can only generate ~80000 reads on a 30 min run.
Leave a comment:
-
-
How much will 1kb reads help with that versus 400bp reads?Originally posted by kmcarr View PostPlant transcriptomics. With so many recent segmental or whole genome duplications in plants assembling paralogous transcripts from shorter reads can be maddening.
There are probably better solutions than longer reads for such situations. For example, unique tagging every transcript in individual droplets during library generation.
Leave a comment:
-
-
I've been told the Titanium XL+ upgrade should be launched by the end of May, but don't have any more details than that other than that new computing is required to process the data.
It's taken Roche way to long to launch this and they are too quiet regarding any other plans they may have. I believe they have licensed the same semiconductor tech as Ion Torrent so I'm waiting for an announcement one day of a similar platform....
Leave a comment:
-
Latest Articles
Collapse
-
by SEQadmin2
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...-
Channel: Articles
07-20-2026, 11:48 AM -
-
by SEQadmin2
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...-
Channel: Articles
07-09-2026, 11:10 AM -
-
by SEQadmin2
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...-
Channel: Articles
07-08-2026, 05:17 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, 07-24-2026, 12:17 PM
|
0 responses
15 views
0 reactions
|
Last Post
by SEQadmin2
07-24-2026, 12:17 PM
|
||
|
Started by SEQadmin2, 07-23-2026, 11:41 AM
|
0 responses
15 views
0 reactions
|
Last Post
by SEQadmin2
07-23-2026, 11:41 AM
|
||
|
Started by SEQadmin2, 07-20-2026, 11:10 AM
|
0 responses
23 views
0 reactions
|
Last Post
by SEQadmin2
07-20-2026, 11:10 AM
|
||
|
Started by SEQadmin2, 07-13-2026, 10:26 AM
|
0 responses
37 views
0 reactions
|
Last Post
by SEQadmin2
07-13-2026, 10:26 AM
|
Leave a comment: